Compandia spun out of Nottingham Trent University

Spin out

Compandia Ltd, has been spun out of Nottingham Trent University to develop and apply biomarkers to stratify clinical trial populations in drug development. The company says its services can be applied from the earliest phase of target identification through to final product pricing.

Compandia uses mass spectrometry to analyse human samples, producing thousands of data points that define the “biological state” of a person. It then applies bioinformatics to define whether an individual is suitable for inclusion in a drug trial or not.

Compandia’s founding scientists, Robert Rees and Graham Ball, have successfully stratified patient groups across a wide range of conditions in melanoma, prostate and breast cancer, Alzheimer’s disease, gynaecological indications, asthma and infectious diseases.  In two separate cancer studies, Compandia’s scientists have been able to identify patients likely to respond to drugs before they receive the therapy.

Compandia has just raised £265,000 from the Lachesis Fund and £75,000 from Mobius Life Sciences, a fund set up by BioCity Nottingham in collaboration with Nottingham City Council.